当前位置:首页 - 行情中心 - 浙江医药(600216) - 财务分析 - 现金流量表

浙江医药

(600216)

  

流通市值:136.26亿  总市值:136.26亿
流通股本:9.62亿   总股本:9.62亿

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金4,504,384,317.322,152,467,494.588,721,539,348.056,646,605,193.25
  收到的税费返还345,238,593.73221,100,668.61285,978,456.89219,967,162.85
  收到其他与经营活动有关的现金83,503,024.9236,945,902.13123,406,697.0895,816,052.69
  经营活动现金流入小计4,933,125,935.972,410,514,065.329,130,924,502.026,962,388,408.79
  购买商品、接受劳务支付的现金2,406,085,754.181,103,824,099.44,723,833,724.643,950,848,794.26
  支付给职工以及为职工支付的现金566,846,592.13355,817,531.64985,718,949.68772,633,696.82
  支付的各项税费545,984,460.13323,331,597.57638,536,697.14491,762,954.17
  支付其他与经营活动有关的现金616,027,924.49322,576,185.711,559,536,488.611,055,082,826.59
  经营活动现金流出小计4,134,944,730.932,105,549,414.327,907,625,860.076,270,328,271.84
  经营活动产生的现金流量净额798,181,205.04304,964,6511,223,298,641.95692,060,136.95
二、投资活动产生的现金流量:
  收回投资收到的现金419,142,568.18196,550,719.59426,771,794.12290,635,061.97
  取得投资收益收到的现金417,234.547501,074,717.232,238,856.72
  处置固定资产、无形资产和其他长期资产收回的现金净额327,832-200,492,312.39193,981,184.07
  收到的其他与投资活动有关的现金489,559,410.93276,368,513.26583,369,145.09462,965,740.71
  投资活动现金流入小计909,447,045.65472,919,982.851,211,707,968.83949,820,843.47
  购建固定资产、无形资产和其他长期资产支付的现金208,193,588.87140,229,317.07689,143,769.13473,738,828.29
  投资支付的现金425,781,417.86195,436,665.94453,164,069.28291,463,107.44
  支付其他与投资活动有关的现金402,500,000255,677,242.74542,900,000467,841,795.29
  投资活动现金流出小计1,036,475,006.73591,343,225.751,685,207,838.411,233,043,731.02
  投资活动产生的现金流量净额-127,027,961.08-118,423,242.9-473,499,869.58-283,222,887.55
三、筹资活动产生的现金流量:
  取得借款收到的现金495,000,000185,000,000520,000,000485,000,000
  筹资活动现金流入小计495,000,000185,000,000520,000,000485,000,000
  偿还债务支付的现金338,000,000137,000,000573,000,000537,000,000
  分配股利、利润或偿付利息支付的现金11,848,151.425,771,240.27172,291,361.34165,926,625.81
  其中:子公司支付给少数股东的股利、利润--1,984,887.82-
  支付其他与筹资活动有关的现金136,919,330-30,029,514.9229,367,106
  筹资活动现金流出小计486,767,481.42142,771,240.27775,320,876.26732,293,731.81
  筹资活动产生的现金流量净额8,232,518.5842,228,759.73-255,320,876.26-247,293,731.81
四、汇率变动对现金及现金等价物的影响63,636,449.1822,827,650.8311,267,874.7614,146,462.78
五、现金及现金等价物净增加额743,022,211.72251,597,818.66505,745,770.87175,689,980.37
  加:期初现金及现金等价物余额1,965,585,411.061,965,585,411.061,459,839,640.191,459,839,640.19
  期末现金及现金等价物余额2,708,607,622.782,217,183,229.721,965,585,411.061,635,529,620.56
补充资料:
  净利润624,571,156.24-1,020,251,510.18-
  资产减值准备79,707,143.85-263,898,853.78-
  固定资产和投资性房地产折旧340,383,586.5-639,659,876.73-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧340,383,586.5-639,659,876.73-
  无形资产摊销41,490,056.32-82,275,878.61-
  长期待摊费用摊销2,246,163.14-3,539,035.51-
  处置固定资产、无形资产和其他长期资产的损失-178,709.95--3,090,739.73-
  固定资产报废损失1,132,404-8,303,514.39-
  公允价值变动损失-1,276,670.78-21,534,114.35-
  财务费用-90,577,420.59-8,584,495.11-
  投资损失3,372,533.17-8,069,379.83-
  递延所得税-19,334,508.99--42,814,569.64-
  其中:递延所得税资产减少-19,334,508.99--42,814,569.64-
  存货的减少-179,104,430.32--347,256,415.96-
  经营性应收项目的减少250,080,707.79--759,439,761.11-
  经营性应付项目的增加-249,561,761.6-305,365,146.09-
  其他--13,692,854.83-
  现金的期末余额2,708,607,622.78-1,965,585,411.06-
  减:现金的期初余额1,965,585,411.06-1,459,839,640.19-
  现金及现金等价物的净增加额743,022,211.72-505,745,770.87-
公告日期2025-08-262025-04-242025-04-242024-10-25
审计意见(境内)标准无保留意见
TOP↑